jd123
Acute Myeloid Leukemia Refractory
Peking University People's HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Acute Myeloid Leukemia Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ab8939 AB Science | Phase 1/2 | CC |
np137 Centre Leon Berard | Phase 1/2 | CC |
Anti-Siglec-6 Car-T Cell Therapy Xuzhou Medical University | Phase 1/2 | CC |
Ucb-Nk Cells Radboud University Medical Center | Phase 1/2 | CC |
Ciml-Nk Cell Therapy Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
View all 9 →
Same molecule, other indications
jd123 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →